Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AQUAPHYLLIN vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phosphodiesterase-3 (PDE3) inhibitor with additional adenosine receptor antagonism and weak inhibition of phosphodiesterase-4 (PDE4). Increases intracellular c AMP and c GMP, leading to bronchodilation and anti-inflammatory effects.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Maintenance treatment of asthma,Chronic obstructive pulmonary disease (COPD) exacerbations
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
300 mg orally every 6 hours as needed for acute asthma exacerbation; for chronic maintenance, 300 mg orally every 8 hours.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Terminal elimination half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in neonates and up to 30 hours in cirrhosis.
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Primarily hepatic via CYP1A2, with minor contributions from CYP3A4 and CYP2E1.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Renal: 90-95% unchanged; biliary/fecal: <5%.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Approximately 40% bound to albumin.
55–65% bound to plasma proteins, primarily albumin.
0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid.
0.4–0.6 L/kg, indicating distribution into total body water.
Oral: 85-95%; intramuscular: 75-90%.
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
No adjustment required.
No dose adjustment required for renal impairment.
In Child-Pugh Class B or C, reduce dose by 50% and monitor serum theophylline levels.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Loading dose: 5 mg/kg orally. Maintenance: 4 mg/kg orally every 6 hours for children 1-9 years; 3 mg/kg orally every 6 hours for children 10-16 years. Maximum daily dose: 24 mg/kg.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Use lower initial dose (e.g., 200 mg orally every 8 hours) and titrate slowly; monitor serum theophylline levels due to decreased clearance.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
None
No FDA black box warning exists for this drug.
Cardiovascular events: arrhythmias, tachycardia, hypotension,Seizures in patients with history of seizure disorder,Significant drug interactions with CYP1A2 inhibitors (e.g., cimetidine, fluoroquinolones) and inducers (e.g., smoking, rifampin),Overdose risk: narrow therapeutic index, monitor serum levels
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to theophylline or other xanthines,Active seizure disorders (relative),Uncontrolled cardiac arrhythmias
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
Avoid large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase theophylline levels and risk of toxicity. High-protein, low-carbohydrate diets may decrease theophylline metabolism; low-protein, high-carbohydrate diets may increase metabolism. Consistent dietary habits are recommended. Charcoal-broiled meats may increase metabolism.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
Theophylline (Aquaphyllin) is pregnancy category C. First trimester: No well-controlled studies; risk cannot be ruled out. Second/third trimesters: Increased risk of neonatal apnea, tachycardia, and jitteriness due to transplacental passage. Maternal toxicity at high doses may cause fetal hypoxia.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Theophylline is excreted in breast milk with M/P ratio approximately 0.6-0.7. Infant plasma levels may reach 10-50% of maternal levels. Monitor infant for irritability, insomnia, and feeding difficulties. Use caution and consider alternative agents if infant is premature or has cardiovascular disease.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
Pregnancy increases theophylline clearance by 30-50% due to increased hepatic metabolism and renal perfusion. Dose may need to be increased by 30% to maintain therapeutic levels (5-15 mcg/m L). Monitor serum levels frequently and adjust accordingly.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
Aquaphyllin (theophylline) has a narrow therapeutic index; serum levels should be maintained between 5-15 mcg/m L for optimal bronchodilation. Monitor for toxicity (nausea, vomiting, tremor, tachycardia) especially in patients with hepatic impairment, heart failure, or concurrent use of CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine). Smoking induces theophylline metabolism requiring higher doses. Use with caution in elderly and patients with seizure disorders.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid consuming large amounts of caffeine-containing foods or beverages (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity such as persistent nausea, vomiting, rapid or irregular heartbeat, or seizures immediately.,Do not stop taking this medication abruptly; taper under medical supervision.,Inform your doctor of all medications you take, including over-the-counter drugs and herbal supplements.,If you smoke, tell your doctor; changes in smoking habits may require dose adjustment.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AQUAPHYLLIN vs AEROLATE SR, answered by our medical review team.
AQUAPHYLLIN is a Bronchodilator that works by Phosphodiesterase-3 (PDE3) inhibitor with additional adenosine receptor antagonism and weak inhibition of phosphodiesterase-4 (PDE4). Increases intracellular c AMP and c GMP, leading to bronchodilation and anti-inflammatory effects.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AQUAPHYLLIN and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AQUAPHYLLIN is: 300 mg orally every 6 hours as needed for acute asthma exacerbation; for chronic maintenance, 300 mg orally every 8 hours.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AQUAPHYLLIN and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AQUAPHYLLIN is classified as Category C. Theophylline (Aquaphyllin) is pregnancy category C. First trimester: No well-controlled studies; risk cannot be ruled out. Second/third trimesters: Increased risk of neonatal apnea. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.